Unknown

Dataset Information

0

Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.


ABSTRACT:

Background

[corrected] Acute decompensated heart failure (ADHF) is a common and highly morbid cardiovascular disorder. Diuresis is a major therapy for the reduction of congestive symptoms. However, most diuretics cause hyponatremia, which is a worsening factor of ADHF patients prognosis. The purpose of this study was to examine the efficacy and safety of tolvaptan, which is a selective vasopressin V2 receptor antagonist and produces water excretion without changes in sodium excretion, compared with carperitide.

Methods and results

One hundred and nine hospitalized ADHF patients were enrolled and randomly assigned to tolvaptan or carperitide treatment groups. Subjective symptoms and plasma BNP level were similarly improved by treatment in both groups. Urine volume was significantly higher in the tolvaptan group (P?ConclusionsTolvaptan might be a novel promising agent for ADHF in terms of efficacy and safety compared to carperitide.

SUBMITTER: Suzuki S 

PROVIDER: S-EPMC4258069 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.

Suzuki Satoshi S   Yoshihisa Akiomi A   Yamaki Takayoshi T   Sugimoto Koichi K   Kunii Hiroyuki H   Nakazato Kazuhiko K   Abe Yukihiko Y   Saito Tomiyoshi T   Ohwada Takayuki T   Suzuki Hitoshi H   Saitoh Shu-ichi S   Kubota Isao I   Takeishi Yasuchika Y  

Journal of clinical pharmacology 20131019 12


<h4>Background</h4>[corrected] Acute decompensated heart failure (ADHF) is a common and highly morbid cardiovascular disorder. Diuresis is a major therapy for the reduction of congestive symptoms. However, most diuretics cause hyponatremia, which is a worsening factor of ADHF patients prognosis. The purpose of this study was to examine the efficacy and safety of tolvaptan, which is a selective vasopressin V2 receptor antagonist and produces water excretion without changes in sodium excretion, co  ...[more]

Similar Datasets

| S-EPMC5071712 | biostudies-literature
| S-EPMC7373889 | biostudies-literature
| S-EPMC5122625 | biostudies-literature
| S-EPMC5613036 | biostudies-literature
| S-EPMC3934929 | biostudies-literature
| S-EPMC7612444 | biostudies-literature
| S-EPMC10579092 | biostudies-literature
| S-EPMC7272393 | biostudies-literature
| S-EPMC8604725 | biostudies-literature
| S-EPMC10386224 | biostudies-literature